Clinical Trial Update: High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating high-dose methotrexate in combination with thiotepa and zanubrutinib for newly diagnosed primary central nervous system l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Methotrexate (high-dose) (Methotrexate)
• THIOTEPA (THIOTEPA)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL) | Phase 2 | Status: NOT_YET_RECRUITING